2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
8
Colorectal Neoplasms
6
Neoplasms by Site
4
Digestive System Neoplasms
4
Pancreatic Neoplasms
3
Neoplasms, Glandular and Epithelial
3
Digestive System Diseases
3
Pancreatic Diseases
2
Neoplasms by Histologic Type
2
Endocrine Gland Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Adenocarcinoma
2
Thymus Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Previously Treated Metastatic Colorectal Cancer
1
Pancreatic cancer, adult
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Interventions
Carboplatin
346
Cisplatin
240
Paclitaxel
208
Radiotherapy
207
Pemetrexed
190
Docetaxel
170
Gemcitabine
158
pembrolizumab
147
Erlotinib Hydrochloride
111
Magnetic Resonance Spectroscopy
102
Etoposide
99
Bevacizumab
96
Specimen Handling
84
Nivolumab
77
Radiosurgery
74
durvalumab
73
Blood Specimen Collection
65
Drug Therapy
61
osimertinib
56
Vinorelbine
54
Gefitinib
50
Surveys and Questionnaires
48
atezolizumab
45
Biopsy
43
Radiation
42
Irinotecan
42
Topotecan
39
Standard of Care
39
Cyclophosphamide
38
Surgical Procedures, Operative
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts